Anti-LRRK2 antibody [MJFF2 (c41-2)] - BSA and Azide free
- KO Validated
- RabMAb
- Recombinant
- What is this?
Be the first to review this product! Submit a review
|
(4 Publications)
Rabbit Recombinant Monoclonal LRRK2 antibody. Carrier free. Suitable for IP, WB and reacts with Human, Mouse samples. Cited in 4 publications.
View Alternative Names
PARK8, LRRK2, Leucine-rich repeat serine/threonine-protein kinase 2, Dardarin
- IP
Lab
Immunoprecipitation - Anti-LRRK2 antibody [MJFF2 (c41-2)] - BSA and Azide free (AB172378)
This data was developed using ab133474, the same antibody clone in a different buffer formulation.
LRRK2 was immunoprecipitated from 0.35 mg A549 (Human lung carcinoma epithelial cell) whole cell lysate 10 μg with 133474 at 1/60 dilution (2μg). VeriBlot for IP Detection Reagent (HRP)(ab131366) was used at 1/5000 dilution.
Lane 1 : A549 (Human lung carcinoma epithelial cell) whole cell lysate 10 μg
Lane 2 : ab133474 IP in A549 whole cell lysate
Lane 3 : Rabbit monoclonal IgG (ab172730) instead of ab133474 in A549 whole cell lysate
Blocking and dilution buffer and concentration : 5% NFDM/TBST.
Fresh lysate should be used to minimize protein degradation.
All lanes:
Immunoprecipitation - Anti-LRRK2 antibody [MJFF2 (c41-2)] (<a href='/en-us/products/primary-antibodies/lrrk2-antibody-mjff2-c41-2-ab133474'>ab133474</a>)
Predicted band size: 286 kDa
Observed band size: 286 kDa
false
- WB
Lab
Western blot - Anti-LRRK2 antibody [MJFF2 (c41-2)] - BSA and Azide free (AB172378)
This WB data was generated using the same anti-LRRK2 antibody clone, MJFF2 (c41-2), in a different buffer formulation (cat# ab133474).
Lane 1 : Wild type A549 whole cell lysate (20 μg)
Lane 2 : Wild type MEF whole cell lysate (20 μg)
Lane 3 : LRRK2 knockout A549 whole cell lysate (20 μg)
Lane 4 : LRRK2 knockout MEF whole cell lysate (20 μg)
Lanes 1 - 4 : Merged signal (red and green). Green - ab133474 observed at 286 kDa. Red - loading control, ab18058, observed at 130 kDa.
ab133474 was shown to recognize LRRK2 in wild type A549 and MEF cells along with additional cross reative bands. Whilst signal was not seen in LRRK2 knockout cells. Wild-type and LRRK2 knockout samples were subjected to SDS-PAGE. ab133474 and ab18058 (Mouse anti Vinculin loading control) were incubated overnight at 4°C at 10000 dilution and 1/10000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed ab216773 and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed ab216776 secondary antibodies at 1/10000 dilution for 1 hour at room temperature before imaging.
Wild-type and LRRK2 knockout MEF and A549 cells were provide as a generous gift from Professor Dario Alessi, MRC Protein Phosphorylation and Ubiquitination Unit (University of Dundee).
All lanes:
Western blot - Anti-LRRK2 antibody [MJFF2 (c41-2)] (<a href='/en-us/products/primary-antibodies/lrrk2-antibody-mjff2-c41-2-ab133474'>ab133474</a>)
Predicted band size: 286 kDa
false
- WB
Lab
Western blot - Anti-LRRK2 antibody [MJFF2 (c41-2)] - BSA and Azide free (AB172378)
This data was developed using ab133474, the same antibody clone in a different buffer formulation.
ab133474 was shown to react with LRRK2 in wild-type A549 cells in Western blot with loss of signal observed in a LRRK2 knockout cell line. Wild-type A549 and LRRK2 knockout cell lysates were subjected to SDS-PAGE. Membranes were blocked in 5% milk in TBST for 1 hr before incubation with ab133474 overnight at 4 °C at a 1/10000 dilution. Blots were incubated with secondary antibodies at 0.2 µg/mL before imaging.
These data were provided by YCharOS Inc., an open science company with the mission of characterizing commercially available antibody reagents for all human proteins. Abcam and YCharOS are working together to help address the reproducibility crisis by enabling the life science community to better evaluate commercially available antibodies.
All lanes:
Western blot - Anti-LRRK2 antibody [MJFF2 (c41-2)] (<a href='/en-us/products/primary-antibodies/lrrk2-antibody-mjff2-c41-2-ab133474'>ab133474</a>) at 1/10000 dilution
Lane 1:
Wild-type A549 lysate at 25 µg
Lane 2:
LRRK2 knock-out A549 lysate at 25 µg
false
Related conjugates and formulations (1)
-
Anti-LRRK2 antibody [MJFF2 (c41-2)]
Reactivity data
Product details
ab172378 is the carrier-free version of ab133474.
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
Collaborations
This antibody was developed with support from The Michael J. Fox Foundation.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
LRRK2 interacts with cellular mechanisms by regulating cytoskeletal dynamics autophagy and vesicle trafficking. It is a part of a larger complex that includes other proteins involved in these processes. The kinase activity of LRRK2 plays an essential part in maintaining neuronal health and function. It influences the process of autophagy which is a way cells clean themselves by removing damaged components and recycling them.
Pathways
The action of LRRK2 is central to the mitogen-activated protein kinase (MAPK) and the mammalian target of rapamycin (mTOR) pathways. In these pathways LRRK2 interacts with other proteins such as mTOR and RPS6KB1. It modulates cellular processes like growth proliferation and response to stressors. Its kinase activity affects the phosphorylation state of targets within the pathways hence influencing biological outcomes like survival and apoptosis.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (4)
Recent publications for all applications. Explore the full list and refine your search
STAR protocols 5:103336 PubMed39356640
2024
Applications
Unspecified application
Species
Unspecified reactive species
Molecular neurodegeneration 19:47 PubMed38862989
2024
Applications
Unspecified application
Species
Unspecified reactive species
NPJ Parkinson's disease 9:44 PubMed36973269
2023
Applications
Unspecified application
Species
Unspecified reactive species
Cell death discovery 6:45 PubMed32550012
2020
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com